$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000143774922018920 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$57.10M	$59.52M	$45.74M
YoY Change	23.48%	11.49%	-53.41%
Cost Of Revenue	$12.50M	$14.92M	$10.84M
YoY Change	21.56%	24.64%	-63.31%
Gross Profit	$44.61M	$44.60M	$34.89M
YoY Change	24.03%	7.69%	-49.15%
Gross Profit Margin	78.12%	74.94%	76.29%
Selling, General & Admin	$23.96M	$20.58M	$20.40M
YoY Change	-8.14%	-47.79%	-27.75%
% of Gross Profit	53.72%	46.13%	58.47%
Research & Development	$11.25M	$11.97M	$15.24M
YoY Change	-40.26%	-35.8%	-24.67%
% of Gross Profit	25.23%	26.83%	43.67%
Depreciation & Amortization	$200.0K	$100.0K	$200.0K
YoY Change	0.0%	-50.0%	0.0%
% of Gross Profit	0.45%	0.22%	0.57%
Operating Expenses	$35.21M	$32.54M	$35.64M
YoY Change	-21.61%	-53.52%	-26.47%
Operating Profit	$2.393M	$12.06M	-$747.0K
YoY Change	-126.73%	-172.49%	-103.71%
Interest Expense	$2.947M	$2.702M	$2.664M
YoY Change	-5.58%	-23.19%	-22.78%
% of Operating Profit	123.15%	22.41%
Other Income/Expense, Net	-$2.686M	-$2.630M	-$2.619M
YoY Change	-92.47%	-122.74%	-26.84%
Pretax Income	-$293.0K	$9.428M	-$3.366M
YoY Change	-99.34%	-286.03%	-120.32%
Income Tax	$67.00K	$57.00K	$37.00K
% Of Pretax Income		0.6%
Net Earnings	-$360.0K	$9.371M	-$3.403M
YoY Change	-99.19%	-283.53%	-120.59%
Net Earnings / Revenue	-0.63%	15.74%	-7.44%
Basic Earnings Per Share	-$0.01	$0.21	-$0.08
Diluted Earnings Per Share	-$0.01	$0.21	-$0.08
COMMON SHARES
Basic Shares Outstanding	45.56M	45.06M	42.21M
Diluted Shares Outstanding	45.57M	45.36M	42.21M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.96M	$60.75M	$73.91M
YoY Change	-10.95%	-44.25%	-32.26%
Cash & Equivalents	$77.96M	$52.76M	$63.91M
Short-Term Investments	$0.00	$7.998M	$9.994M
Other Short-Term Assets	$4.110M	$4.291M	$631.0K
YoY Change	811.31%	797.7%	69.17%
Inventory	$5.452M	$6.665M	$7.277M
Prepaid Expenses	$6.801M	$8.583M	$8.716M
Receivables	$28.03M	$33.99M	$27.04M
Other Receivables	$3.525M	$8.482M	$5.138M
Total Short-Term Assets	$122.4M	$114.3M	$117.6M
YoY Change	-10.64%	-31.88%	-28.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.282M	$1.435M	$1.591M
YoY Change	-33.37%	-31.63%	-30.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.968M	$3.095M	$4.030M
YoY Change	-36.45%	-35.09%	-12.39%
Total Long-Term Assets	$76.42M	$79.37M	$83.12M
YoY Change	-14.49%	-13.96%	-12.38%
TOTAL ASSETS
Total Short-Term Assets	$122.4M	$114.3M	$117.6M
Total Long-Term Assets	$76.42M	$79.37M	$83.12M
Total Assets	$198.8M	$193.7M	$200.7M
YoY Change	-12.16%	-25.52%	-22.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.93M	$9.841M	$7.412M
YoY Change	-25.54%	-11.87%	-30.43%
Accrued Expenses	$39.69M	$41.30M	$61.84M
YoY Change	-56.28%	-38.35%	-22.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$59.99M	$56.83M	$74.79M
YoY Change	-48.4%	-58.79%	-46.73%
LONG-TERM LIABILITIES
Long-Term Debt	$97.99M	$97.68M	$97.38M
YoY Change	1.23%	42.17%	27.55%
Other Long-Term Liabilities	$18.63M	$19.40M	$21.37M
YoY Change	-22.83%	-18.92%	-16.2%
Total Long-Term Liabilities	$97.99M	$97.68M	$97.38M
YoY Change	1.23%	5.46%	27.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.99M	$56.83M	$74.79M
Total Long-Term Liabilities	$97.99M	$97.68M	$97.38M
Total Liabilities	$176.6M	$173.9M	$193.5M
YoY Change	-25.54%	-24.56%	-20.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.361B	-$1.361B	-$1.370B
YoY Change	-0.72%
Common Stock	$1.383B	$1.381B	$1.377B
YoY Change	1.71%		2.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.16M	$19.74M	$7.145M
YoY Change
Total Liabilities & Shareholders Equity	$198.8M	$193.7M	$200.7M
YoY Change	-12.16%	-25.52%	-22.43%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$360.0K	$9.371M	-$3.403M
YoY Change	-99.19%	-283.53%	-120.59%
Depreciation, Depletion And Amortization	$200.0K	$100.0K	$200.0K
YoY Change	0.0%	-50.0%	0.0%
Cash From Operating Activities	$17.26M	-$13.87M	-$26.90M
YoY Change	64.4%	18905.48%	-271.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$7.998M	$1.997M	$8.982M
YoY Change	-278.93%	-134.84%	-269.47%
Cash From Investing Activities	$7.998M	$1.997M	$8.982M
YoY Change	-278.93%	-134.84%	-269.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-53.00K	0.000	$9.845M
YoY Change	-99.83%
NET CHANGE
Cash From Operating Activities	17.26M	-13.87M	-$26.90M
Cash From Investing Activities	7.998M	1.997M	$8.982M
Cash From Financing Activities	-53.00K	0.000	$9.845M
Net Change In Cash	25.20M	-11.88M	-$8.068M
YoY Change	-197.31%	104.6%	-177.88%
FREE CASH FLOW
Cash From Operating Activities	$17.26M	-$13.87M	-$26.90M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52756000	usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45274635
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45274635
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41175507
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41175507
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	200000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	200000	usd
CY2022Q2	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	1	pure
CY2021	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8000000.0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8000000.0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8000000.0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8000000.0	usd
CY2022Q2	pbyi	Finitelived Intangible Asset Expected Amortization Year Six FinitelivedIntangibleAssetExpectedAmortizationYearSix	8000000.0	usd
CY2022Q2	pbyi	Finitelived Intangible Asset Expected Amortization Year Seven FinitelivedIntangibleAssetExpectedAmortizationYearSeven	8000000.0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2500000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2000000.0	usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35703
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0683487
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10880 Wilshire Boulevard, Suite 2150
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
	dei	City Area Code CityAreaCode	424
	dei	Local Phone Number LocalPhoneNumber	248-6500
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	PBYI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45555963
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63131000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7998000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18975000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33987000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32526000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	6665000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7109000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8583000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8984000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4291000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	447000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	114280000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	140022000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12723000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14017000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1435000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1756000	usd
CY2022Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	62118000	usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	66125000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2591000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	504000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1354000	usd
CY2022Q2	us-gaap	Assets Assets	193651000	usd
CY2021Q4	us-gaap	Assets Assets	226585000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9841000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11174000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41297000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92575000	usd
CY2022Q2	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	1856000	usd
CY2021Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	2263000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3840000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3574000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	56834000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109586000	usd
CY2022Q2	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	37000	usd
CY2021Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	915000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13983000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15975000	usd
CY2022Q2	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5377000	usd
CY2021Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5463000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97682000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97092000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	173913000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	229031000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1380522000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1364309000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59518000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53384000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1360789000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1366757000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	19738000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2446000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193651000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226585000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	105254000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	151553000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14918000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11969000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	25762000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41527000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20576000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39410000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40978000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	67748000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11966000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18638000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27203000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38866000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	47460000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	70017000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	93943000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	148141000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	12058000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16633000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	11311000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	3412000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	65000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	121000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	78000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	134000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	2702000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	3518000	usd
	us-gaap	Interest Expense InterestExpense	5366000	usd
	us-gaap	Interest Expense InterestExpense	6968000	usd
CY2022Q2	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-55000	usd
CY2021Q2	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	14902000	usd
	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-73000	usd
	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	14717000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	60000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	112000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	102000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2630000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11565000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5249000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7985000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9428000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5068000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6062000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11397000	usd
	us-gaap	Net Income Loss NetIncomeLoss	11322000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9371000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5968000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45058924
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40479577
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43641193
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40370825
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45358739
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40479577
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43889556
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40939688
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9371000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5968000	usd
	us-gaap	Net Income Loss NetIncomeLoss	11322000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	9372000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5107000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5970000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11321000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7145000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3220000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9371000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	19738000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16337000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18239000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5106000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29469000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2446000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6368000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9846000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5968000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	19738000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4486000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24099000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	usd
	us-gaap	Net Income Loss NetIncomeLoss	11322000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29469000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5968000	usd
	us-gaap	Net Income Loss NetIncomeLoss	11322000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5886000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6368000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	24099000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1461000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4006000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-444000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4166000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1251000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-271000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3844000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3163000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1333000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-910000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-52156000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-18503000	usd
	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-493000	usd
	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-569000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40769000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15587000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	-0	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	19117000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	10979000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	8085000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10979000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11032000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	155000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9845000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19945000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4555000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75292000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97454000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	55347000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	102009000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	20000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4776000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4550000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	141000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	84000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	6000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40800000	usd
CY2022Q2	pbyi	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	60800000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43641000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40371000
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	300000
CY2021Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	248000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Use of Estimates: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles ("GAAP") in the United States, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p>
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7836905000
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9434076000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8051317000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8048926000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9371000	usd
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	569000
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45359000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40480000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43890000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40940000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5968000	usd
	us-gaap	Net Income Loss NetIncomeLoss	11322000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45059000
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40480000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2022Q2	pbyi	Sublease Agreement Potential Milestone Payments SubleaseAgreementPotentialMilestonePayments	579800000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	2600000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	12200000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	45922000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	usd
CY2022Q2	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	45921000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	69849000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
CY2021Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	69847000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Concentration of Risk: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at <em style="font: inherit;"> June 30, 2022</em> were approximat<span style="background-color:#ffffff;">ely </span>$55.2<span style="background-color:#ffffff;"> million. </span>The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on <em style="font: inherit;">one</em> or more <em style="font: inherit;">third</em>-party contractors to manufacture the commercial supply of drugs.</p>
CY2022Q2	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	55200000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2903000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4569000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3120000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1385000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	642000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1155000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	6665000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7109000	usd
CY2022Q2	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109	pure
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4000000.0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	4000000.0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8000000.0	usd
CY2022Q2	pbyi	Finitelived Intangible Asset Expected Amortization Year Eight FinitelivedIntangibleAssetExpectedAmortizationYearEight	2000000.0	usd
CY2022Q2	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	25505000	usd
CY2021Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	29646000	usd
CY2022Q2	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	8482000	usd
CY2021Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	2880000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	33987000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	32526000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q2	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	271000	usd
CY2021Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	340000	usd
CY2022Q2	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	2824000	usd
CY2021Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	2933000	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	1557000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3178000	usd
CY2022Q2	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	1064000	usd
CY2021Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	398000	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2867000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2135000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8583000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8984000	usd
CY2022Q2	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	160000	usd
CY2021Q4	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	166000	usd
CY2022Q2	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	129000	usd
CY2021Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	577000	usd
CY2022Q2	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	215000	usd
CY2021Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	611000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	504000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1354000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	9087000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	10338000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2500000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5983000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2754000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5631000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5805000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2926000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1508000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21681000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3858000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	17823000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	100000	usd
	us-gaap	Sublease Income SubleaseIncome	200000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	243000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	495000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	510000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	525000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	134000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1907000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8572000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8617000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7137000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6861000	usd
CY2021Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	911000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1435000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1756000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	100000	usd
	us-gaap	Depreciation Depreciation	300000	usd
CY2022Q2	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	usd
CY2021Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27882000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23875000	usd
CY2022Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	62118000	usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	66125000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4000000.0	usd
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y9M18D
CY2022Q2	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	2912000	usd
CY2021Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	57137000	usd
CY2022Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	11334000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8829000	usd
CY2022Q2	pbyi	Accrued Development Costs AccruedDevelopmentCosts	2311000	usd
CY2021Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	2663000	usd
CY2022Q2	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	11676000	usd
CY2021Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	11406000	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3198000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5083000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4152000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3878000	usd
CY2022Q2	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	2573000	usd
CY2022Q2	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	822000	usd
CY2021Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	672000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1485000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	674000	usd
CY2022Q2	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	582000	usd
CY2021Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	690000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	252000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	632000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41297000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92575000	usd
CY2022Q2	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	0	usd
CY2021Q4	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	878000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	usd
CY2022Q2	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	37000	usd
CY2021Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	915000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	41334000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	93490000	usd
CY2021Q4	pbyi	Restructuring Percentage Of Reduction In Headcount RestructuringPercentageOfReductionInHeadcount	0.13	pure
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102000000	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4318000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97682000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	33997000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	45329000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	22674000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	102000000	usd
CY2022Q2	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	1092000	usd
CY2021Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	502000	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4318000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4908000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	400000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	pbyi	Ordinary Shares Ownership Percentage OrdinarySharesOwnershipPercentage	0.20	pure
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1100000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3220000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18239000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6368000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24099000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.32
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	835297
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	482353
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	262386
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	8.14
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1055264
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.87
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1000000.0	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1000000.0	usd
CY2022Q2	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000	usd
	pbyi	Percentage Of Unpaid Portion Of Milestone Payments Interest Rate PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate	0.0625	pure
CY2021Q3	pbyi	Milestone Payment MilestonePayment	1800000	usd

Files In Submission

Name	View Source	Status
0001437749-22-018920-index-headers.html	Edgar Link	pending
0001437749-22-018920-index.html	Edgar Link	pending
0001437749-22-018920.txt	Edgar Link	pending
0001437749-22-018920-xbrl.zip	Edgar Link	pending
ex_380812.htm	Edgar Link	pending
ex_380813.htm	Edgar Link	pending
ex_380814.htm	Edgar Link	pending
ex_380815.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-20220630.xsd	Edgar Link	pending
pbyi-20220630_cal.xml	Edgar Link	unprocessable
pbyi-20220630_def.xml	Edgar Link	unprocessable
pbyi-20220630_lab.xml	Edgar Link	unprocessable
pbyi-20220630_pre.xml	Edgar Link	unprocessable
pbyi20220630_10q.htm	Edgar Link	pending
pbyi20220630_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2022 Q3 Form 10-Q Financial Statement

#000143774922018920 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2022 Q3 Form 10-Q Financial Statement

#000143774922018920 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi